• Home
  • News
  • U.S. Weightlifting Athlete Michael Zoda Accepts Sanction for Non-Analytical Anti-Doping Rule Violation

U.S. Weightlifting Athlete Michael Zoda Accepts Sanction for Non-Analytical Anti-Doping Rule Violation

USADA Logo

Press Release

8th January 2018

USADA announced today that Michael Zoda of Yardley, Pa., an athlete in the sport of weightlifting, has accepted a two-year sanction for a non-analytical

anti-doping rule violation after admitting to his possession and use of prohibited substances. 

In 2016, USADA obtained non-analytical evidence that Zoda, 27, received prohibited substances in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics that are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List. 

During its investigation regarding prohibited peptides used in sport and purchased over the internet, USADA approached Zoda, who admitted to purchasing and using peptides he received from an online retailer, and agreed to cooperate with USADA’s investigation. Due to Zoda’s cooperation and substantial assistance in establishing that another athlete committed an anti-doping rule violation, Zoda was eligible for and received a reduced sanction under the Code.

Zoda’s two-year period of ineligibility, which was reduced from the default four-year period of ineligibility, began on August 13, 2016, the date he admitted to his violation. In addition, Zoda has been disqualified from all competitive results obtained on and subsequent to March 1, 2015, the date he first purchased prohibited substances in violation of applicable rules, including forfeiture of any medals, points and prizes.

The use of prohibited peptides by athletes and consumers for performance or physique enhancement purposes (including recovery from injury) poses serious health risks, and these peptides are not approved by the FDA for human use or consumption. These products, often branded as for “research/laboratory use only,” have not received any human clinical safety or efficacy evaluation, and are not produced according to Current Good Manufacturing Practice (CGMP) regulations. As such, they may cause serious adverse health effects, including immune and toxicity reactions, infection, and even death.

Leave a comment

Please login to leave a comment.

Courses

Legal Advisors

Upcoming Events


Copyright © LawInSport Limited 2010 - 2022. These pages contain general information only. Nothing in these pages constitutes legal advice. You should consult a suitably qualified lawyer on any specific legal problem or matter. The information provided here was accurate as of the day it was posted; however, the law may have changed since that date. This information is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. LawInSport is not responsible for any actions taken or not taken on the basis of this information. Please refer to the full terms and conditions on our website.